Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rhea-AI Summary

Rein Therapeutics (NASDAQ: RNTX) has published research in Biomedicines highlighting the therapeutic potential of their LTI-2355 peptide for treating Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F).

The study demonstrates that LTI-2355, a soluble and proteolysis-resistant 13-mer CSD peptide, improved the phagocytic activity of IPF and PASC-F myeloid cells while reducing their pro-inflammatory and pro-fibrotic synthetic activity. The research was conducted using lung explant tissue from donors and patients with IPF and PASC-F.

The manuscript was authored by Rein's leadership team, including BreAnne MacKenzie, Cory M. Hogaboam, and Brian Windsor, along with researchers from Cedars-Sinai Medical Center and Duke University.

Positive

• Publication in peer-reviewed journal validates scientific approach
• LTI-2355 shows dual therapeutic action: improved phagocytic activity and reduced pro-inflammatory response
• Successful preclinical results in both IPF and PASC-F conditions

Negative

• Research still in preclinical stage, requiring further clinical validation
• No data on human clinical efficacy presented

Insights

Biotechnology Research Analyst

The publication in Biomedicines represents an incremental validation step for Rein Therapeutics' scientific approach to treating fibrotic diseases. Their caveolin scaffolding domain (CSD) peptide LTI-2355 demonstrated dual-action capabilities in laboratory studies using human tissue samples: improving phagocytic (immune cell) activity while simultaneously reducing pro-inflammatory and pro-fibrotic responses in cells from both Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) patients.

This preclinical research suggests LTI-2355 could potentially address multiple disease mechanisms in fibrotic lung conditions. The inclusion of co-authors from prominent research institutions (Cedars-Sinai Medical Center and Duke University) adds scientific credibility to their approach.

For context, IPF is a serious, progressive lung disease with significant unmet medical needs despite recent therapeutic advances. The company's focus on both traditional IPF and COVID-related fibrosis demonstrates an effort to address emerging conditions alongside established diseases.

However, this remains preclinical research, representing an early validation step in drug development. The path from laboratory findings to approved therapies typically requires years of clinical trials and significant investment. For Rein Therapeutics, with its $36.5 million market capitalization, this publication supports their scientific foundation while highlighting the substantial development work that remains ahead.

Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F)

AUSTIN, Texas, April 15, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines.

The manuscript, titled "Caveolin Scaffolding Domain (CSD) Peptide LTI-2355 Modulates the Phagocytic and Synthetic Activity of Lung-Derived Myeloid Cells in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F)," describes the effects of caveolin scaffolding domain (CSD) peptide LTI-2355 on the immune and synthetic properties of human lung-derived macrophages and other myeloid cells isolated from lung explant tissue of donor lungs, as well as IPF and PASC-F lung explant tissue. LTI-2355 is a soluble and proteolysis-resistant 13-mer CSD peptide with anti-fibrotic properties that has been used in several preclinical models of fibrosis. In the present study, LTI-2355 improved the phagocytic (i.e., anti-infective) activity of both IPF and PASC-F myeloid cells compared with control peptide-treated cells, and this improvement coincided with decreased pro-inflammatory and pro-fibrotic synthetic activity of the diseased cells.

The article was authored by BreAnne MacKenzie, Ph.D., Director of Translational Research, Cory M. Hogaboam, Ph.D., Chief Scientific Officer, and Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. The article's co-authors included investigators from Cedars-Sinai Medical Center and Duke University.

"The acceptance of this paper in Biomedicines validates our science and highlights the therapeutic importance of CSD peptides in IPF and other forms of fibrosis," said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. "This data demonstrates that LTI-2355 modifies both the innate activation and profibrotic synthetic properties of myeloid cells from fibrotic lung conditions. These results indicate that LTI-2355 effectively reduces both inflammatory and fibrotic properties of myeloid cells, which contribute to the progression and exacerbation of lung fibrosis. We are focused on reining in fibrosis and advancing our pipeline of novel candidates, aiming to bring hope to those affected by pulmonary fibrosis and other fibrotic conditions."

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. For more information, please visit the company's website at reintx.com, or follow them on LinkedIn and X.

Forward-Looking Statements

This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the timing and expectation of a Phase 2 trial of LTI-03; and future expectations, plans and prospects for the Company. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in the Company's drug discovery; preclinical and clinical development activities; the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials, including in a Phase 2 trial of LTI-03, or that partial results of a trial will be indicative of the full results of the trial; the Company's ability to enroll patients in its clinical trials; and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all; decisions made by the U.S. Food and Drug Administration and other regulatory authorities; investigational review boards at clinical trial sites and publication review bodies with respect to the our development candidates; our ability to obtain, maintain and enforce intellectual property rights for our platform and development candidates; competition; the sufficiency of the Company's cash resources to fund its planned activities for the periods anticipated and the Company's ability to manage unplanned cash requirements; and general economic and market conditions; as well as the risks and uncertainties discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which are on file with the United States Securities and Exchange Commission (the "SEC") and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company's view as of any date after the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Rein Investor Relations & Media Contact:
Argot Partners
rein@argotpartners.com
212-600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/rein-therapeutics-announces-a-publication-in-biomedicines-on-the-immunomodulatory-and-anti-fibrotic-properties-of-a-caveolin-1-related-peptide-in-ipf-and-pasc-f-302428229.html

SOURCE Rein Therapeutics, Inc.

FAQ

What are the key findings of RNTX's LTI-2355 study in treating pulmonary fibrosis?

LTI-2355 improved phagocytic activity in IPF and PASC-F myeloid cells while reducing pro-inflammatory and pro-fibrotic activity, showing potential in treating lung fibrosis conditions.

Which institutions collaborated with Rein Therapeutics (RNTX) on the LTI-2355 research?

The research involved collaboration between Rein Therapeutics, Cedars-Sinai Medical Center, and Duke University.

What conditions does RNTX's LTI-2355 peptide target?

LTI-2355 targets Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F).

What type of peptide is RNTX's LTI-2355 and what are its properties?

LTI-2355 is a soluble and proteolysis-resistant 13-mer Caveolin Scaffolding Domain (CSD) peptide with anti-fibrotic properties.